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It is well known that uremia causes an increase in the serum
anion gap (AG); however, whether changes in the AG occur
earlier in the course of chronic kidney disease is not known.
Here we investigated whether different measures of the AG,
as a marker of kidney function, are associated with mortality.
To do this, we analyzed the available laboratory data of
11,957 adults in the National Health and Nutrition
Examination Survey 1999–2004 to calculate AG using the
traditional method, or one that was albumin-adjusted, as
well as a full AG reflecting other electrolytes. A significant
elevation in the traditional AG was seen only with an
estimated glomerular filtration rate (eGFR) o45ml/
minper 1.73m2, whereas increases in the albumin-adjusted
and full AG were found with eGFRs o60 or 90ml/
minper 1.73m2, respectively. Higher levels of each AG were
associated with an increased risk of all-cause mortality after
adjustment for age, gender, race/ethnicity, and eGFR. After
adjustment for additional covariates including body mass
index and comorbidities, higher levels of the albumin-
adjusted and full AG were associated with mortality (relative
hazard for the highest compared with the lowest quartile
were 1.62 and 1.64, respectively). Thus, higher levels of AG
are present in individuals with less advanced kidney disease
than previously recognized, and are associated with
increased risk of mortality. Further study is needed to identify
the unmeasured anions and to determine their physiological
significance.
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It is well known that uremia causes an increase in the serum
anion gap (AG) due to the accumulation of a variety of
solutes. Whether changes in the AG occur earlier in the
course of chronic kidney disease (CKD) has been little
explored. Previous studies in persons with CKD have
demonstrated an increase in the AG only with relatively
advanced kidney disease.1–3 Studies of the general population
have supported this view.4,5 However, variations in the serum
albumin concentration affect the AG,6 and these studies have
not accounted for the hypoalbuminemia that commonly
accompanies progressive kidney disease.4 Therefore, the AG
may increase earlier in the course of CKD than has been
previously recognized. Such changes may be of prognostic
significance as higher levels of the AG have been associated
with hypertension, insulin resistance, and low cardiorespira-
tory fitness in nationally representative populations largely
free of advanced kidney disease.7–9 Calculation of the AG
after accounting for electrolyte measurements that are not
traditionally included, in addition to the serum albumin,
could also yield a measurement with greater specificity for
the accumulation of organic anions.
We hypothesized that after accounting for changes in
albumin and other electrolytes, (1) higher levels of AG would
be present in persons with relatively preserved glomerular
filtration rate (GFR), and (2) higher AG would be associated
with increased risk of mortality in individuals without
advanced kidney disease. We tested these hypotheses using
data from participants in the National Health and Nutrition
Examination Survey (NHANES) 1999–2004.
RESULTS
Participant characteristics
The AG was calculated in the traditional manner (tradi-
tional), after adjustment for serum albumin (albumin-
adjusted), and after adjustment for serum albumin and
other electrolytes (full) (depicted graphically in Figure 1).
The mean levels of AG were 12.08 (standard error (s.e.) 0.15),
1.20 (s.e. 0.15), and 5.45 (s.e. 0.16) mEq/l for the traditional,
albumin-adjusted, and full AG, respectively. Participants with
higher traditional AG were more likely to have lower edu-
cation and physical activity levels, more likely to have hyper-
tension and diabetes, and had higher levels of hemoglobin,
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serum albumin, and calcium, and lower serum bicarbonate
(Supplementary eTable S1 online). Participants with higher
albumin-adjusted or full AG were older, more likely to be
women, had higher BMI and lower education and physical
activity levels, and were more likely to have hypertension,
diabetes, cardiovascular disease (CVD), low estimated GFR
(eGFR), and microalbuminuria, and had lower serum
bicarbonate (Supplementary eTable S2 online and Table 1,
respectively). Participants with higher full AG also had higher
levels of hemoglobin and lower serum albumin and
phosphate. Each 1 mEq/l increment in the traditional,
albumin-adjusted, and full AG was associated with a 0.42
(95% confidence interval (CI) 0.38–0.47), 0.47 (95% CI
0.43–0.51), and 0.46 (95% CI 0.41–0.50) mEq/l lower serum
bicarbonate, respectively.
Association of AG with GFR
Compared with participants with Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI)–defined eGFR
90–119 ml/min per 1.73 m2, the traditional AG was signifi-
cantly elevated only among those with eGFR 30–44 ml/
min per 1.73 m2 (Table 2, upper panel). Using the albumin-
adjusted and full definitions, there was a graded rise in AG
across eGFR categories beginning with eGFR 45–59 and
60–89 ml/min per 1.73 m2, respectively. When eGFRcys was
calculated using cystatin C levels in 4,132 participants, there
was a graded rise in AG with lower eGFRcys for all three AG
definitions (Table 2, lower panel). Compared with partici-
pants with eGFRcys 90–119 ml/min per 1.73 m
2, higher AG
was seen beginning with eGFRcys 30–44 ml/min per 1.73 m
2
for the traditional AG and beginning with eGFRcys 60–89 ml/
min per 1.73 m2 for the albumin-adjusted and full AG. A
similar pattern was seen for the association of age-adjusted
AG with eGFR and eGFRcys categories (Figure 2).
Association of AG with all-cause mortality
During a median 57 months follow-up time (interquartile
range 39–74), 729 participants died. When examined as
continuous variables, higher levels of each AG were
associated with increased risk of all-cause mortality in
unadjusted analyses and after adjustment for age, sex, race/
ethnicity, and eGFR (Table 3). In fully adjusted models, only
the albumin-adjusted and full AG were associated with
mortality as continuous variables. Compared with partici-
pants in the lowest quartiles of albumin-adjusted and full AG,
there was a significantly increased risk of mortality among
those in the highest quartile of each in unadjusted models
and after adjustment for age, sex, and race/ethnicity, which
was little changed by additional adjustment for eGFR. In fully
adjusted models, there was no association of traditional AG
with mortality but there remained a significant association of
higher albumin-adjusted and full AG with all-cause mortality
(relative hazard for highest versus lowest quartile, 1.52 (95%
CI 1.17–1.97) for albumin-adjusted AG and 1.53 (95% CI
1.11–2.11) for full AG, respectively.) Additional analyses
exploring the effect of albuminuria demonstrated that log-
transformed urine albumin–creatinine ratio (UACR) was a
confounder of the association of each AG with mortality
(Supplementary eTable S3 online). The association of full AG
with mortality did not vary across quartiles of serum
phosphate or albumin, respectively (Figure 3). After adding
serum albumin and phosphate to the fully adjusted model,
the relative hazard for mortality per s.d. higher full AG was
1.17 (95% CI 1.01–1.36); for participants in the highest
quartile of full AG, compared with the lowest, the relative
hazard was 1.48 (95% CI 1.08–2.02).
Sensitivity analyses. After excluding participants with
eGFR o60 ml/min per 1.73 m2, higher levels of the albu-
min-adjusted and full AG were associated with an increased
risk of mortality (Table 4). These results were unchanged
after excluding participants with either eGFR o60 ml/
min per 1.73 m2 or macroalbuminuria. A similar, although
nonsignificant, trend remained after further excluding
participants with microalbuminuria. To explore if our
findings would differ with adjustment for cystatin C-based
vs. creatinine-based eGFR, we examined mortality in the
subgroup of participants with measurement of cystatin C.
Our estimates were similarly attenuated by adjustment for
CKD-EPI eGFR as by adjustment for eGFRcys (Table 5).
Finally, we examined the independent association of serum
bicarbonate with mortality. Higher serum bicarbonate was
associated with an increased risk of mortality in unadjusted
models, and this association was no longer significant after
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Figure 1 |Graphical depiction of components of the anion
gap (AG) in each version of the calculation. Anion gap¼
Unmeasured anions (UA) – Unmeasured cations (UC). UA
and UC are determined by the anions and cations that are
accounted for in the calculation. Each panel depicts the
components included in each AG calculation. The following
definitions were used: Traditional AG¼ serum sodium(mEq/l) –
(serum chloride(mEq/l)þ serum bicarbonate(mEq/l)); Albumin-
adjusted AG¼ Traditional AG – (2.5 serum albumin(g/dl)); Full
AG¼Albumin-adjusted AGþ serum potassium(mEq/l)þ ionized
calcium(mEq/l) – serum phosphate(mEq/l). The traditional AG
calculation includes only Naþ , Cl, and HCO3
. As additional
anions and cations are accounted for in the calculation of the
albumin-adjusted and full AG, the unmeasured components
(UA and UC) become smaller.
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adjustment for age, sex, and race/ethnicity (Supplementary
eTable S4 online).
DISCUSSION
Our results demonstrate that higher levels of AG are present in
persons with less advanced kidney disease than has been
previously recognized, and that this association is dependent
upon the definition of AG utilized. Changes in serum albumin
account for much of the difference between our results and
previous studies, although including other electrolytes in the
calculation further increased the magnitude of the association
of AG levels with eGFR. Measurement of eGFR using cystatin
C improved the robustness of the association, with a linear
increase in AG seen with eGFRcys below 90 ml/min per 1.73 m
2.
After accounting for serum albumin and other electrolytes,
higher levels of AG were associated with an increased risk of
all-cause mortality, independent of multiple factors including
eGFR and albuminuria. Estimation of GFR using cystatin C
did not appear to alter these findings. These results suggest
that small yet measurable increases in typically unmeasured
anions may be present earlier in the course of kidney disease
than is currently appreciated, and that these compounds may
be markers for, or have a causal role in, the association of CKD
with an increased risk for mortality.
We may speculate about the composition of higher
levels of AG based on previous literature. In a study of 57
Table 1 | Participant characteristics by quartiles of full anion gap in 11,957 participants of NHANES 1999–2004
Full anion gap (mEq/l)
Characteristic o3.62 3.62–5.35 5.36–7.23 47.23 P
Number 2783 3044 3033 3097
Age (years) 44.1 (0.3) 46.1 (0.5) 46.6 (0.5) 47.9 (0.5) o0.001
Women (%) 47.1 (1.0) 51.4 (1.3) 51.9 (1.0) 52.6 (1.0) o0.001
Race/ethnicity (%) 0.46
Non-Hispanic white 72.6 (2.1) 72.5 (2.0) 71.9 (2.4) 72.6 (2.7)
Mexican American 7.8 (1.1) 7.7 (1.1) 7.0 (1.1) 6.5 (1.3)
Non-Hispanic black 9.6 (1.1) 11.7 (1.2) 10.1 (1.0) 9.3 (1.8)
Body mass index (kg/m2) o0.001
o20 5.8 (0.5) 5.3 (0.6) 5.0 (0.6) 5.1 (0.5)
20–25 34.2 (1.3) 29.6 (0.9) 28.7 (1.1) 24.0 (1.1)
25–29 36.0 (0.9) 34.2 (1.2) 35.2 (1.4) 34.0 (1.0)
30–35 15.7 (0.7) 19.7 (1.0) 18.5 (0.8) 20.1 (0.8)
435 8.2 (0.7) 11.3 (0.9) 12.5 (0.9) 16.7 (0.9)
Less than high school diploma (%) 16.6 (1.2) 18.5 (0.9) 22.0 (1.0) 23.1 (1.2) o0.001
Activity level (MET, min/week, %) o0.001
0 12.7 (0.8) 15.0 (0.8) 17.8 (0.9) 20.7 (1.7)
o500 20.8 (1.1) 22.8 (0.8) 20.1 (1.2) 19.9 (0.9)
500–2000 37.0 (1.1) 37.3 (0.9) 34.3 (1.1) 32.0 (1.3)
42000 29.5 (1.2) 24.9 (1.2) 27.9 (1.3) 27.4 (1.6)
Smoking (%) 0.13
Never 53.1 (1.1) 50.4 (1.2) 47.6 (1.3) 48.6 (2.4)
Former 24.5 (1.1) 24.3 (0.9) 26.0 (1.1) 26.0 (1.4)
Current 22.4 (1.3) 25.3 (1.1) 26.4 (1.2) 25.4 (1.4)
Hypertension (%) 32.6 (1.3) 39.3 (1.3) 41.5 (1.2) 47.2 (1.6) o0.001
Diabetes mellitus (%) 4.0 (0.5) 6.4 (0.7) 8.2 (0.6) 9.9 (0.7) o0.001
Cardiovascular disease (%) 5.3 (0.6) 8.5 (0.8) 9.2 (0.7) 10.7 (0.7) o0.001
eGFR (ml/min per 1.73m2) o0.001
15–59 3.7 (0.4) 5.7 (0.6) 6.7 (0.5) 9.2 (0.6)
60–89 34.9 (1.4) 34.7 (1.4) 35.9 (1.2) 35.4 (0.9)
90–119 50.7 (1.3) 49.4 (1.5) 48.0 (1.3) 46.7 (1.2)
X120 10.6 (0.8) 10.2 (0.7) 9.4 (0.7) 8.8 (0.8)
UACR430mg/g (%) 5.8 (0.6) 8.7 (0.7) 9.6 (0.6) 12.9 (0.8) o0.001
Hemoglobin (g/dl) 14.49 (0.05) 14.44 (0.06) 14.55 (0.05) 14.64 (0.07) 0.02
Serum bicarbonate (mEq/l) 25.5 (0.1) 24.6 (0.1) 23.8 (0.1) 22.6 (0.1) o0.001
Serum albumin (g/dl) 4.40 (0.01) 4.32 (0.01) 4.34 (0.01) 4.34 (0.01) 0.03
Serum calcium (mg/dl) 9.49 (0.02) 9.49 (0.01) 9.47 (0.02) 9.49 (0.02) 0.61
Serum phosphate (mg/dl) 3.70 (0.02) 3.71 (0.01) 3.63 (0.02) 3.59 (0.02) o0.001
Abbreviations: eGFR, estimated glomerular filtration rate; MET, metabolic equivalent; NHANES, National Health and Nutrition Examination Survey; UACR, urinary albumin-
creatinine ratio.
Data are expressed as mean (s.e.) or percentage (s.e.).
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hospitalized patients, lactate and ketoanions accounted for
62% of the increment in the traditional AG, and changes in
proteins, potassium, phosphate, and calcium accounted for
an additional 15%.10 An average of 23% of the increased AG
was unaccounted for, suggesting the possibility of unidenti-
fied anions or changes in other normal plasma components.
This study, however, examined hospitalized patients with
levels of traditional AG greater than 16 mEq/l, in marked
contrast to our study of community-dwelling participants
with a mean traditional AG of 12.08 mEq/l. Therefore, it is
unclear to what degree these previous results can be
extrapolated to our findings.
Differences in AG may be due to solutes known to
accumulate in advanced kidney disease.11 Tubular secretion is
an important contributor to the clearance of a number of
compounds whose levels rise in uremia, such as the nega-
tively charged hippurate.12 Loss of tubular function causes
elevated concentrations of various organic anions,13 and the
accumulation of organic solutes is known to contribute to the
high AG metabolic acidosis seen in advanced kidney
disease.14 Whether impairment of tubular function occurs
earlier in the course of CKD is unknown. Disruption of renal
organic anion secretion could result in higher concentrations
of endogenous organic anions, as demonstrated in a mouse
knockout model of organic anion transporter 1.13 Mild
impairment of proximal tubular function early in the course
of kidney disease could result in small increases in the levels
of such solutes. Over 70 years ago, Shannon postulated renal
tubular excretion as a mechanism for minimizing levels of
endogenous toxins, such that deficiencies in tubular function
could account for some of the symptomatology of kidney
disease.15 Nevertheless, tubular handling of organic solutes
remains a relatively understudied aspect of kidney function,
especially as it relates to the clinical phenotype of persons with
CKD. Alternatively, mild impairment in glomerular filtration
may be sufficient to account for the retention of non-chloride
anions that were not included in our calculation of the full
AG, as acid retention has been demonstrated in subjects with
only mild reductions in eGFR.16 Alterations in circulating
proteins other than albumin could also produce changes in
the AG. Thus, the AG may represent a cumulative measure of
the changes in a number of circulating factors that occur even
with mild impairment of kidney function. Indeed, our results
were unchanged after the exclusion of participants with eGFR
o60 ml/min per 1.73m2, suggesting that the AG, as a marker
for the retention of various solutes and possibly a measure of
tubular function, may provide a more sensitive measure of
impaired kidney function among individuals with eGFR
X60 ml/min per 1.73 m2.
Higher AG may also reflect increased concentrations of
organic anions present in persons with obesity, insulin resis-
tance, and hypertension. In the general population, higher
levels of the traditional AG have been associated with
hypertension and insulin resistance.7,8 The association with
insulin resistance, in particular, was of greater magnitude in
obese individuals. This suggests a relationship between
Table 2 | Levels of anion gap by categories of CKD-EPI and cystatin C-based eGFR in participants of NHANES 1999–2004
Traditional anion gap (mEq/l) Albumin-adjusted anion gap (mEq/l) Full anion gap (mEq/l)
Mean (s.e.) Change Mean (s.e.) Change Mean (s.e.) Change
Anion gap by CKD-EPI eGFR category in 11,957 participants
eGFR
X120 (n=1330) 12.05 (0.16) 0.03 (0.28 to 0.22) 1.14 (0.16) 0.005 (0.25 to 0.26) 5.24 (0.16) 0.11 (0.37 to 0.15)
90–119 (n=5288) 12.08 (0.17) Ref. 1.13 (0.17) Ref. 5.35 (0.17) Ref.
60–89 (n=4210) 12.04 (0.15) 0.04 (0.17 to 0.10) 1.20 (0.15) 0.07 (0.06 to 0.20) 5.49 (0.16) 0.14 (0.01 to 0.27)
45–59 (n=792) 12.21 (0.18) 0.13 (0.16 to 0.42) 1.67 (0.17) 0.54 (0.27 to 0.81) 6.07 (0.18) 0.72 (0.43 to 1.00)
30–44 (n=259) 12.65 (0.24) 0.56 (0.28 to 0.85) 2.29 (0.25) 1.15 (0.87 to 1.43) 6.78 (0.25) 1.43 (1.15 to 1.70)
15–29 (n=78) 12.17 (0.26) 0.09 (0.46 to 0.63) 2.02 (0.33) 0.89 (0.25 to 1.53) 6.55 (0.30) 1.20 (0.63 to 1.76)
P trend* 0.006 o0.001 o0.001
o15 (n=24) 16.02 (0.66) 3.94 (2.66 to 5.23) 5.53 (0.57) 4.39 (3.26 to 5.53) 9.20 (0.70) 3.85 (2.49 to 5.21)
Anion gap by cystatin C eGFR category in 4,132 participants
eGFR
X120 (n=307) 12.81 (0.24) 0.11 (0.34 to 0.56) 1.60 (0.26) 0.04 (0.48 to 0.39) 5.86 (0.26) 0.06 (0.50 to 0.37)
90–119 (n=1169) 12.70 (0.23) Ref. 1.64 (0.23) Ref. 5.92 (0.24) Ref.
60–89 (n=1865) 12.91 (0.24) 0.21 (0.04 to 0.46) 2.08 (0.22) 0.43 (0.20 to 0.67) 6.39 (0.22) 0.47 (0.21 to 0.72)
45–59 (n=537) 13.07 (0.36) 0.37 (0.22 to 0.95) 2.47 (0.35) 0.83 (0.30 to 1.35) 6.82 (0.37) 0.90 (0.33 to 1.46)
30–44 (n=208) 13.20 (0.23) 0.50 (0.15 to 0.86) 2.83 (0.25) 1.19 (0.87 to 1.51) 7.34 (0.24) 1.42 (1.10 to 1.74)
15–29 (n=52) 13.67 (0.37) 0.97 (0.28 to 1.67) 3.24 (0.40) 1.59 (0.85 to 2.34) 7.72 (0.35) 1.80 (1.17 to 2.42)
P trend* 0.006 o0.001 o0.001
o15 (n=15) 17.36 (0.66) 4.66 (3.29 to 6.02) 6.69 (0.40) 5.04 (4.14 to 5.95) 10.90 (0.60) 4.98 (3.73 to 6.23)
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; NHANES, National Health and Nutrition Examination
Survey; s.e., standard error.
*P values calculated without including participants with eGFR o15ml/min per 1.73m2 in the analysis.
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obesity, insulin resistance, and the metabolic syndrome, and
the solutes accounting for higher levels of AG. The
attenuation of mortality risk by adjustment for BMI, activity
level, diabetes, hypertension, and CVD may be reflective of
this relationship. If so, our results indicate that measurements
of organic solutes may be predictive of mortality in such
individuals. Alternatively, as obesity and the metabolic
syndrome are risk factors for the development of CKD and
end-stage renal disease,17,18 the attenuation of our estimates
could signal subtle impairment of kidney function, mani-
fested as higher AG, in persons with components of the
metabolic syndrome.
The association of albumin-adjusted and full AG with
mortality could be reflective of the known inverse association
of serum albumin with mortality risk; by definition, lower
albumin levels result in higher albumin-adjusted and full AG.
However, the difference in serum albumin across full AG
quartiles, while statistically significant, was quite small. In
addition, the association of full AG with mortality did not
vary across quartiles of serum albumin. Similarly, the
association of full AG with mortality did not vary across
serum phosphate quartiles, and participants with higher
phosphate levels, which have been associated with mortality,
would have lower AG. Furthermore, adjustment for serum
albumin and phosphate did not alter our results. Therefore,
independent associations of albumin or phosphate seem an
unlikely explanation for our findings.
Similarly, the association of higher AG with increased
mortality does not appear to be mediated by the effects of
acidosis. Serum bicarbonate was not independently asso-
ciated with mortality, and the estimates of mortality risk
associated with the AG were independent of serum
bicarbonate. Therefore, these data do not support a role
for alkali therapy for an elevated AG per se. Rather, such
therapeutic decisions should be based on the degree of
acidosis and the evidence base informing the treatment of
acidosis. Similarly, we cannot comment on whether indivi-
duals with a high albumin-adjusted or full AG but normal
serum bicarbonate have a low-grade metabolic acidosis that
could be amenable to alkali therapy. As alkali may be
beneficial even in early CKD,19 this should be the subject of
future research.
Several important limitations of our analysis should be
noted. Estimation of the charge contribution of serum
albumin, calcium, and phosphate could have been performed
more precisely had values of blood pH or ionized calcium
been available. However, the participants in this study were
sampled from the general population, and the vast majority
would be expected to have pH values within the normal
range. Differences of 0.05–0.10 pH units within the range of
physiologic pH would have negligible effects on our estimates
of charge contribution. We employed the generally accepted
adjustments for serum albumin and phosphate and tested
different assumptions for the estimation of ionized calcium,
which had no effect on our results. Thus, we believe that
differences in full AG levels represent differences in the
concentrations of solutes not included in our calculation,
rather than simply imprecise charge estimation. Our
calculations did not account for changes in serum sulfate,
which is known to accumulate in uremia, because it was not
measured in NHANES. We also did not have measures of
magnesium. However, the lack of accounting for possibly
higher magnesium levels in persons with CKD would have
resulted in falsely low AG levels, which would have reduced
the likelihood of detecting significant associations with eGFR
or mortality. In addition, levels of AG were determined from
single measurements, and variability in sample handling may
affect bicarbonate levels.20–22 GFR estimation using cystatin C
levels may be affected by factors such as inflammation.23
Finally, as this was an observational study, we cannot infer
causality regarding the associations seen.
In conclusion, higher levels of AG are present in persons
with less advanced kidney disease than has been previously
recognized, and are associated with an increased risk of
mortality independent of eGFR and albuminuria. Further
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Figure 2 |Mean age-standardized anion gap by categories
of creatinine-based Chronic Kidney Disease Epidemiology
Collaboration estimated glomerular filtration rate in 11,957
participants (upper panel) and cystatin C-based estimated
glomerular filtration rate in 4,132 participants (lower panel)
of NHANES 1999–2004.
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research is needed to identify the molecules accounting for
higher levels of AG in persons without advanced kidney
disease and to determine their physiological significance.
MATERIALS AND METHODS
Study population
NHANES 1999–2004 was a nationally representative survey of the
non-institutionalized civilian population in the United States.24 A
stratified, multistage, probability sampling design was used to select
participants. Overall, 13,269 adults X20 years of age completed
the interview and examination components, and had complete
laboratory data for each of the AG definitions. We excluded
participants who were pregnant (n¼ 716), missing mortality data
(n¼ 17), had an eGFRo15 ml/min per 1.73 m2 (n¼ 42), or missing
covariate data (n¼ 537). Thus, 11,957 participants were available
for analysis. In the analyses of the association of AG with eGFR,
participants with eGFR o15 ml/min per 1.73 m2 were included for
comparison. The Committee on Clinical Investigation at the Albert
Einstein College of Medicine determined this analysis to be exempt.
Data collection
Information on education, physical activity, smoking, and comor-
bidities was obtained by self-report. Race/ethnicity was self-
identified. Participants were asked about the frequency and duration
of walking or bicycling, home or yard work, and moderate or
vigorous leisure time physical activity performed within the past 30
days. These responses were used to calculate metabolic equivalents
Table 3 | Relative hazard of all-cause mortality by anion gap quartile in 11,957 participants of NHANES 1999–2004
Relative hazard (95% CI)
Anion gap Model 1 Model 2 Model 3 Model 4
Traditional
Continuousa 1.15 (1.02–1.29) 1.15 (1.03–1.29) 1.14 (1.02–1.27) 1.08 (0.94–1.24)
Quartile 1 Ref. Ref. Ref. Ref.
Quartile 2 0.86 (0.66–1.12) 0.86 (0.67–1.10) 0.86 (0.67–1.10) 0.83 (0.64–1.07)
Quartile 3 1.01 (0.76–1.35) 0.99 (0.75–1.32) 0.98 (0.74–1.30) 0.90 (0.66–1.23)
Quartile 4 1.30 (0.96–1.74) 1.32 (1.01–1.72) 1.29 (1.00–1.67) 1.20 (0.89–1.61)
P for trend 0.04 0.02 0.03 0.15
Albumin adjusted
Continuousa 1.40 (1.25–1.58) 1.28 (1.14–1.44) 1.27 (1.13–1.42) 1.19 (1.03–1.38)
Quartile 1 Ref. Ref. Ref. Ref.
Quartile 2 1.36 (1.05–1.76) 1.29 (0.99–1.67) 1.27 (0.99–1.64) 1.24 (0.97–1.59)
Quartile 3 1.30 (1.00–1.70) 1.19 (0.91–1.56) 1.18 (0.91–1.53) 1.07 (0.82–1.38)
Quartile 4 2.17 (1.62–2.91) 1.82 (1.37–2.41) 1.76 (1.34–2.32) 1.62 (1.19–2.21)
P for trend o0.001 o0.001 o0.001 0.007
Full
Continuousa 1.50 (1.33–1.68) 1.29 (1.15–1.45) 1.28 (1.14–1.43) 1.20 (1.03–1.41)
Quartile 1 Ref. Ref. Ref. Ref.
Quartile 2 1.67 (1.22–2.29) 1.40 (1.01–1.94) 1.36 (0.98–1.89) 1.31 (0.97–1.79)
Quartile 3 1.59 (1.19–2.13) 1.28 (0.95–1.72) 1.26 (0.94–1.68) 1.19 (0.90–1.57)
Quartile 4 2.68 (1.87–3.83) 1.88 (1.31–2.70) 1.82 (1.28–2.59) 1.64 (1.17–2.31)
P for trend o0.001 0.001 0.001 0.01
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; NHANES, National Health and Nutrition Examination Survey.
Bold values indicate Po0.05.
Quartile cutoff levels for each anion gap definition: Traditional: Q1 p10; Q2 10.1–12; Q3 12.1–14; Q4 X14.1mEq/l; Albumin adjusted: Q1p 0.50; Q2 0.45–1.05; Q3
1.10–2.95; Q4 X3mEq/l; Full: Q1 p3.61; Q2 3.62–5.34; Q3 5.35–7.23; Q4 47.23mEq/l.
Model 1: unadjusted.
Model 2: adjusted for age, sex, and race/ethnicity.
Model 3: adjusted for age, sex, race/ethnicity, and eGFR categories.
Model 4: adjusted for age, sex, race/ethnicity, eGFR categories, body mass index, education, activity level, smoking status, diagnosis of diabetes mellitus, hypertension,
cardiovascular disease, log-transformed urine albumin–creatinine ratio, serum bicarbonate, and hemoglobin.
aPer s.d. higher anion gap (traditional s.d.=2.55mEq/l; albumin-adjusted s.d.=2.47mEq/l; full s.d.=2.49mEq/l).
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Figure 3 |Unadjusted relative hazard of all-cause mortality per
one standard deviation higher full anion gap (s.d.¼ 2.49 mEq/l)
within quartiles of serum phosphate (upper panel) and albumin
(lower panel) in 11,957 participants of NHANES 1999–2004.
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(MET-min/week)25 and to classify activity level as 0, o500,
500–2000, or 42000 MET-min/week. Smoking was classified as
never, former, or current smoker. Hypertension was defined as a
systolic blood pressure X140 mm Hg, diastolic blood pressure
X90 mm Hg, physician diagnosis, and/or antihypertensive medica-
tion use.26 Diabetes mellitus was defined as a physician diagnosis
while not pregnant or the current use of insulin or oral
hypoglycemic medications. CVD was defined by self-report of a
physician diagnosis of congestive heart failure, coronary heart
disease, angina, myocardial infarction, or stroke.
Serum chemistry values were measured using the Hitachi 917
multichannel analyzer (Roche Diagnostics, Indianapolis, IN) in
1999–2001 and the Beckman Synchron LX20 (Beckman Coulter,
Brea, CA) in 2002–2004. Serum sodium, potassium, and chloride
were measured with an ion-selective electrode, albumin by the
bromocresol purple method, phosphate via reaction with ammo-
nium molybdate, and calcium via reaction with O-cresolphthalein
complexone in 1999–2001 and by ion-selective electrode in
2002–2004. Serum bicarbonate was measured via the phosphoenol-
pyruvate carboxylase method from 1999–2001 and with a pH-
sensitive electrode in 2002–2004. The AG was calculated in three
ways, using ionic contributions of electrolytes and albumin based
on the published literature (Figure 1): traditional AG¼ serum
sodium(mEq/l)–(serum chloride(mEq/l)þ serum bicarbonate(mEq/l));
albumin-adjusted AG¼ traditional AG–(2.5 serum albumin(g/dl));27
and full AG¼ albumin-adjusted AGþ serum potassium(mEq/l)þ
ionized calcium(mEq/l)–serum phosphate(mEq/l), where we assumed
50% of calcium existed in the ionized form and a valence of 1.8
for inorganic phosphate at physiologic pH,28 such that ionized
calcium(mEq/l)¼ (0.5x (total calcium(mg/dl) þ 0.8 (4–serum
albumin(g/dl))/2) and serum phosphate (mEq/l)¼ (0.323 serum
phosphate(mg/dl))  1.8. Given the imprecision with adjustment of
total calcium for albumin and the variation of the ionized fraction
by pH, all analyses were repeated without adjustment of total calcium
for albumin and also assuming an ionized fraction of 40% or 60%. As
the results did not differ, only the analyses with the initial definition
of full AG are presented.
Serum creatinine was measured by a modified kinetic Jaffe´
reaction. Values from 1999–2000 were calibrated to the Cleveland
Clinic laboratory standard by multiplying by 1.013 and then adding
0.147. Correction of values from 2001–2004 was not necessary. eGFR
was calculated using the CKD-EPI equation.29 Serum cystatin C
was measured in a subsample of participants in 1999–2002 using a
particle-enhanced nephelometric assay. eGFRcys was calculated using
age, sex, race, and cystatin C.23 Appropriate sample weights were
used to account for the smaller sample in which cystatin C levels
were available.
Outcome variables
All-cause mortality was ascertained through 31 December 2006
using public-use-linked mortality files.30 Mortality status was deter-
mined primarily through probabilistic record matching with the
National Death Index. Complete details of the matching methodo-
logy are available.31 The public-use files were subjected to data
Table 4 | Sensitivity analyses of associations of anion gap with all-cause mortality in 11,957 participants of NHANES 1999–2004
Relative hazard (95% CI)
Anion gap Traditional Albumin adjusted Full
Relative hazard among participants with eGFR X60ml/minper 1.73m2 (n=10,828; 467 deaths)
Continuousa 1.17 (1.00–1.37) 1.31 (1.13–1.52) 1.30 (1.12–1.51)
Quartile 1 Ref. Ref. Ref.
Quartile 2 0.76 (0.51–1.13) 1.38 (0.92–2.05) 1.34 (0.88–2.04)
Quartile 3 0.92 (0.62–1.37) 1.02 (0.71–1.48) 1.07 (0.72–1.60)
Quartile 4 1.34 (0.91–1.96) 1.86 (1.24–2.78) 1.79 (1.17–2.75)
P for trend 0.06 0.007 0.01
Relative hazard among participants with eGFR X60ml/minper 1.73m2 and UACR o300mg/g (n=10,697; 446 deaths)
Continuousa 1.14 (0.97–1.34) 1.28 (1.10–1.50) 1.27 (1.09–1.48)
Quartile 1 Ref. Ref. Ref.
Quartile 2 0.76 (0.51–1.14) 1.37 (0.92–2.03) 1.32 (0.86–2.00)
Quartile 3 0.93 (0.64–1.37) 1.03 (0.70–1.50) 1.06 (0.71–1.60)
Quartile 4 1.28 (0.87–1.88) 1.84 (1.24–2.73) 1.76 (1.16–2.68)
P for trend 0.10 0.008 0.01
Relative hazard among participants with eGFR X60ml/minper 1.73m2 and UACRo30mg/g (n=9700; 324 deaths)
Continuousa 1.07 (0.86–1.33) 1.21 (0.98–1.48) 1.20 (0.99–1.46)
Quartile 1 Ref. Ref. Ref.
Quartile 2 0.70 (0.43–1.14) 1.45 (0.89–2.36) 1.24 (0.78–1.99)
Quartile 3 0.75 (0.50–1.12) 0.99 (0.63–1.57) 1.05 (0.66–1.67)
Quartile 4 1.10 (0.63–1.91) 1.55 (0.91–2.63) 1.45 (0.85–2.48)
P for trend 0.63 0.21 0.24
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; NHANES, National Health and Nutrition Examination Survey; UACR, urinary albumin-
creatinine ratio.
Bold values indicate Po0.05.
Quartile cutoff levels for each anion gap definition: Traditional: Q1p10; Q2 10.1–12; Q3 12.1–14; Q4X14.1mEq/l; Albumin adjusted: Q1p0.50; Q20.45–1.05; Q3 1.10–2.95;
Q4X3mEq/l; Full: Q1p3.61; Q2 3.62–5.34; Q3 5.35–7.23; Q447.23 mEq/l.
Models adjusted for age, sex, race/ethnicity, eGFR categories, body mass index, education, activity level, smoking status, diagnosis of diabetes mellitus, hypertension,
cardiovascular disease, log-transformed urine albumin-creatinine ratio, serum bicarbonate, and hemoglobin.
aPer s.d. higher anion gap (traditional s.d.=2.55mEq/l; albumin-adjusted s.d.=2.47mEq/l; full s.d.=2.49mEq/l).
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perturbation techniques due to concerns regarding participant
anonymity. For selected decedent records, the date of death and
cause of death were perturbed. Vital status was not perturbed.
Owing to the perturbation of cause-of-death data, we examined
only all-cause mortality. Analyses performed by the National Center
for Health Statistics demonstrate consistent and nearly identical
numerical results when examining all-cause mortality with Cox
proportional hazards models using the public-use data compared
with non-perturbed restricted-use data.32
Statistical analysis
All analyses used NHANES-appropriate sampling weights and
accounted for the complex multistage cluster design using the
‘survey’ command in Stata 11.1 (Stata, College Station, TX). The
distributions of participant characteristics were examined by
quartiles of each AG. The association of serum bicarbonate with
each AG was also examined using linear regression. The mean
traditional, albumin-adjusted, and full AG were calculated within
categories of eGFR and eGFRcys. Age-standardized mean values of
each AG were then calculated for each eGFR and eGFRcys category
using 2000 US census data. Cox proportional hazards models were
created to examine associations with all-cause mortality. Each AG
was analyzed as a continuous variable and within quartiles to
examine nonlinear associations with mortality. Models were created
examining associations with mortality in the overall cohort without
adjustment for additional covariates and then including age, sex,
race/ethnicity, and eGFR categories as covariates. For survival
analyses, eGFR was categorized as X120, 90–119, 60–89, and
15–59 ml/min per 1.73 m2 due to the relatively small number of
participants with eGFRo60 ml/min per 1.73 m2. Additional models
were created adding log-transformed UACR to the above covariates.
Multivariable models were then created to include as covariates
other potential confounders or mediators of the association of AG
with mortality, including education (as a marker of socioeconomic
status), BMI categories, activity level, smoking status, diagnosis of
diabetes mellitus, hypertension, CVD, serum bicarbonate, and
hemoglobin. We examined the possibility that associations of the
albumin-adjusted and full AG with mortality were driven by the
inclusion in our calculations of serum albumin in both and serum
phosphate in the latter, as both serum albumin and phosphate
have been associated with all-cause mortality.33–35 We therefore
examined the associations of the full AG with mortality within
quartiles of serum albumin and phosphate, respectively, as the
full AG incorporates both albumin and phosphate in the calculation.
We then entered serum albumin and phosphate into an exploratory
model including the above covariates to determine if associations
of full AG with mortality were independent of these measures.
The proportional hazards assumption was shown to be accurate by
visual inspection of log–log plots.
Sensitivity analyses. To determine whether our results were
driven by participants with CKD, we examined associations of
each type of AG with mortality in participants with eGFR
X60 ml/min per 1.73 m2, after excluding those with either eGFR
o60 ml/min per 1.73 m2 or macroalbuminuria (defined as UACR
X300 mg/g), and then after further excluding participants with
microalbuminuria (defined as UACRX30 mg/g). To explore differ-
ences in confounding related to cystatin C-based vs. creatinine-based
eGFR, we repeated our survival analyses in the subgroup of parti-
cipants with cystatin C measurements. We recalculated quartiles of
each AG in this subgroup, and then examined the association of
each AG with mortality in unadjusted models and then in models
adjusted for age, sex, race/ethnicity, and either eGFR or eGFRcys
categories. Finally, we examined the independent association of serum
bicarbonate with mortality, modeling it as a continuous variable and
within quartiles.
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SUPPLEMENTARY MATERIAL
Table S1. Participant Characteristics by Quartiles of Traditional Anion
Gap in 11,957 participants of NHANES 1999-2004.
Table S2. Participant Characteristics by Quartiles of Albumin-
Adjusted Anion Gap in 11,957 participants of NHANES 1999-2004.
Table S3. Relative Hazard of All-Cause Mortality with Revised
Model 3.
Table 5 | Sensitivity analysis of all-cause mortality using
different eGFR adjustments in 4,132 participants of NHANES
1999–2002 with cystatin C measurements (491 deaths)
Relative hazard (95% CI)
Anion gap Unadjusted CKD-EPI eGFR Cystatin C eGFR
Traditional
Continuousa 1.11 (0.92–1.35) 1.14 (0.95–1.36) 1.11 (0.93–1.32)
Quartile 1 Ref. Ref. Ref.
Quartile 2 0.74 (0.48–1.13) 0.83 (0.53–1.29) 0.80 (0.52–1.23)
Quartile 3 0.90 (0.55–1.50) 0.96 (0.57–1.61) 0.94 (0.57–1.54)
Quartile 4 1.14 (0.77–1.69) 1.26 (0.86–1.86) 1.18 (0.81–1.72)
P for trend 0.33 0.15 0.24
Albumin adjusted
Continuousa 1.34 (1.09–1.64) 1.24 (1.05–1.47) 1.20 (1.01–1.42)
Quartile 1 Ref. Ref. Ref.
Quartile 2 0.75 (0.45–1.25) 0.76 (0.47–1.26) 0.77 (0.48–1.24)
Quartile 3 0.92 (0.57–1.49) 0.90 (0.56–1.44) 0.87 (0.56–1.36)
Quartile 4 1.69 (1.12–2.55) 1.42 (0.96–2.10) 1.34 (0.92–1.94)
P for trend 0.009 0.03 0.07
Full
Continuousa 1.45 (1.16–1.80) 1.26 (1.06–1.51) 1.23 (1.02–1.47)
Quartile 1 Ref. Ref. Ref.
Quartile 2 0.65 (0.37–1.14) 0.65 (0.39–1.08) 0.65 (0.39–1.07)
Quartile 3 0.89 (0.54–1.49) 0.80 (0.48–1.32) 0.76 (0.47–1.23)
Quartile 4 1.81 (1.16–2.84) 1.33 (0.88–2.00) 1.24 (0.83–1.84)
P for trend 0.004 0.05 0.11
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate;
NHANES, National Health and Nutrition Examination Survey.
Bold values indicate Po0.05.
Quartile cutoff levels for each anion gap definition: Traditional: Q1p11; Q2 11.1–13;
Q3 13.1–14.6; Q4 X14.7mEq/l; Albumin adjusted: Q1 p0.2; Q2 0.25–1.95; Q3
2.00–3.60; Q4 X3.65mEq/l; Full: Q1 o4.41; Q2 4.41–6.24; Q3 6.25–7.94; Q4
X7.95mEq/l.
Models are unadjusted, or adjusted for age, sex, race/ethnicity, and CKD-EPI or
eGFRcys categories, as noted in the table.
aPer s.d. higher anion gap (traditional s.d.=2.55mEq/l; albumin-adjusted
s.d.=2.47mEq/l; full s.d.=2.49mEq/l).
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Table S4. Relative Hazard of All-Cause Mortality by Serum
Bicarbonate Quartiles in 11,957 participants of NHANES 1999-2004.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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